Triheptanoin (UX007) to Treat Citrate Transporter Deficiency
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether triheptanoin (UX007) is effective in the
treatment of neurological symptoms related to citrate transporter deficiency (SLC13A5 gene
mutation).